{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:33:18Z","timestamp":1792978398194,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s12282-026-01918-4","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:20:48Z","timestamp":1789971648000},"page":"1353-1366","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Triggering receptors expressed on myeloid cells (TREM-1) and TREM-2 as predictors of pathological complete response to neoadjuvant therapy in triple-negative breast cancer"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2988-4450","authenticated-orcid":false,"given":"Nazan","family":"Demir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0382-5396","authenticated-orcid":false,"given":"\u0130vo","family":"G\u00f6kmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7347-263X","authenticated-orcid":false,"given":"Duygu Bay\u0131r","family":"Garbio\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7686-7765","authenticated-orcid":false,"given":"Ebru","family":"Ta\u015ftekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7156-8918","authenticated-orcid":false,"given":"Emre","family":"I\u015f\u0131k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9111-9132","authenticated-orcid":false,"given":"Erkan","family":"\u00d6zcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2158-3490","authenticated-orcid":false,"given":"B\u00fclent","family":"Erdo\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5387-8309","authenticated-orcid":false,"given":"Sernaz","family":"Topalo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4462-6393","authenticated-orcid":false,"given":"Bahad\u0131r","family":"K\u00f6yl\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8604-9988","authenticated-orcid":false,"given":"Cevat \u0130lteri\u015f","family":"K\u0131k\u0131l\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6085-1921","authenticated-orcid":false,"given":"Fatih","family":"Kemik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7584-3868","authenticated-orcid":false,"given":"\u0130rfan","family":"\u00c7i\u00e7in","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1273-1674","authenticated-orcid":false,"given":"Fatih","family":"Sel\u00e7ukbiricik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8490-3239","authenticated-orcid":false,"given":"Muhammet Bekir","family":"Hac\u0131o\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"issue":"11","key":"1918_CR1","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674\u201390. https:\/\/doi.org\/10.1038\/nrclinonc.2016.66.","journal-title":"Nat Rev Clin Oncol"},{"key":"1918_CR2","doi-asserted-by":"publisher","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938-48. https:\/\/doi.org\/10.1056\/NEJMra1001389.","DOI":"10.1056\/NEJMra1001389"},{"key":"1918_CR3","doi-asserted-by":"publisher","unstructured":"Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O\u2019Shaughnessy J. KEYNOTE-522 Investigators. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386(6):556\u2013567. https:\/\/doi.org\/10.1056\/NEJMoa2112651.","DOI":"10.1056\/NEJMoa2112651"},{"key":"1918_CR4","doi-asserted-by":"publisher","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164\u2013172. https:\/\/doi.org\/10.1016\/S0140-6736(13)62422-8.","DOI":"10.1016\/S0140-6736(13)62422-8"},{"key":"1918_CR5","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3389\/fimmu.2020.00784","volume":"11","author":"F Petitprez","year":"2020","unstructured":"Petitprez F, Meylan M, de Reyni\u00e8s A, Saut\u00e8s-Fridman C, Fridman WH. The tumor microenvironment in the response to immune checkpoint blockade therapies. Front Immunol. 2020;11:784. https:\/\/doi.org\/10.3389\/fimmu.2020.00784.","journal-title":"Front Immunol"},{"key":"1918_CR6","doi-asserted-by":"publisher","first-page":"662723","DOI":"10.3389\/fonc.2021.662723","volume":"11","author":"JW Ford","year":"2022","unstructured":"Ford JW, Gonzalez-Cotto M, MacFarlane AW 4th, Peri S, Howard OMZ, Subleski JJ, Ruth KJ, Haseebuddin M, Al-Saleem T, Yang Y, Rayman P, Rini B, Linehan WM, Finke J, Weiss JM, Campbell KS, McVicar DW. Tumor-infiltrating myeloid cells co-express TREM-1 and TREM-2 and elevated TREM-1 associates with disease progression in renal cell carcinoma. Front Oncol. 2022;11:662723. https:\/\/doi.org\/10.3389\/fonc.2021.662723.","journal-title":"Front Oncol"},{"key":"1918_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.pharmthera.2017.02.043","volume":"177","author":"A Tammaro","year":"2017","unstructured":"Tammaro A, Derive M, Gibot S, Leemans JC, Florquin S, Dessing MC. TREM-1 and its potential ligands in non-infectious diseases: from biology to clinical perspectives. Pharmacol Ther. 2017;177:81\u201395. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.02.043.","journal-title":"Pharmacol Ther"},{"key":"1918_CR8","doi-asserted-by":"publisher","unstructured":"Gibot S, Kolopp-Sarda MN, B\u00e9n\u00e9 MC, Cravoisy A, Levy B, Faure GC, Bollaert PE. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Ann Intern Med. 2004;141(1):9\u201315. https:\/\/doi.org\/10.7326\/0003-4819-141-1-200407060-00009.","DOI":"10.7326\/0003-4819-141-1-200407060-00009"},{"key":"1918_CR9","doi-asserted-by":"publisher","unstructured":"Ho CC, Liao WY, Wang CY, Lin MW, Chen KY, Tsai TH et al. TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. Am J Respir Crit Care Med. 2008;177(7):763\u2013770. https:\/\/doi.org\/10.1164\/rccm.200704-641OC.","DOI":"10.1164\/rccm.200704-641OC"},{"key":"1918_CR10","doi-asserted-by":"publisher","unstructured":"Klesney-Tait J, Turnbull IR, Colonna M. The TREM receptor family and signal integration. Nat Immunol. 2006;7(12):1266-73. https:\/\/doi.org\/10.1038\/ni1411.","DOI":"10.1038\/ni1411"},{"issue":"24","key":"1918_CR11","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1212\/WNL.0000000000004747","volume":"89","author":"L Ghezzi","year":"2017","unstructured":"Ghezzi L, Carandini T, Arighi A, Fenoglio C, Arcaro M, De Riz M, Pietroboni AM, Fumagalli GG, Basilico P, Calvi A, Scarioni M, Colombi A, Serpente M, Marotta G, Benti R, Scarpini E, Galimberti D. Evidence of CNS \u03b2-amyloid deposition in Nasu-Hakola disease due to the TREM-2 Q33X mutation. Neurology. 2017;89(24):2503\u20135.","journal-title":"Neurology"},{"issue":"2","key":"1918_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.14283\/jfa.2018.43","volume":"8","author":"C Gussago","year":"2019","unstructured":"Gussago C, Casati M, Ferri E, Arosio B. The Triggering Receptor Expressed on Myeloid Cells-2 (TREM-2) as Expression of the relationship between microglia and alzheimer\u2019s disease: a novel marker for a promising pathway to explore. J Frailty Aging. 2019;8(2):54\u20136. https:\/\/doi.org\/10.14283\/jfa.2018.43.","journal-title":"J Frailty Aging"},{"issue":"1","key":"1918_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1040841X.2022.2146481","volume":"50","author":"AO Matos","year":"2024","unstructured":"Matos AO, Dantas PHDS, Queiroz HAGB, Silva-Sales M, Sales-Campos H. TREM-2: friend or foe in infectious diseases? Crit Rev Microbiol. 2024;50(1):1\u201319.","journal-title":"Crit Rev Microbiol"},{"key":"1918_CR14","doi-asserted-by":"publisher","first-page":"1375729","DOI":"10.3389\/fonc.2024.1375729","volume":"14","author":"X Lei","year":"2024","unstructured":"Lei X, Gou YN, Hao JY, Huang XJ. Mechanisms of TREM-2 mediated immunosuppression and regulation of cancer progression. Front Oncol. 2024;14:1375729. https:\/\/doi.org\/10.3389\/fonc.2024.1375729.","journal-title":"Front Oncol"},{"key":"1918_CR15","doi-asserted-by":"publisher","first-page":"984193","DOI":"10.3389\/fonc.2022.984193","volume":"12","author":"EM Wolf","year":"2022","unstructured":"Wolf EM, Fingleton B, Hasty AH. The therapeutic potential of TREM-2 in cancer. Front Oncol. 2022;12:984193. https:\/\/doi.org\/10.3389\/fonc.2022.984193.","journal-title":"Front Oncol"},{"issue":"2","key":"1918_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41389-018-0115-x","volume":"8","author":"W Tang","year":"2019","unstructured":"Tang W, Lv B, Yang B, Chen Y, Yuan F, Ma L, Chen S, Zhang S, Xia J. TREM-2 acts as a tumor suppressor in hepatocellular carcinoma by targeting the PI3K\/Akt\/\u03b2-catenin pathway. Oncogenesis. 2019;8(2):9. https:\/\/doi.org\/10.1038\/s41389-018-0115-x.","journal-title":"Oncogenesis"},{"key":"1918_CR17","doi-asserted-by":"publisher","first-page":"113750","DOI":"10.1016\/j.intimp.2024.113750","volume":"145","author":"P Yin","year":"2025","unstructured":"Yin P, Jiang H, Ji X, Xia L, Su Z, Tian Y, Soluble. TREM-2 drives triple-negative breast cancer progression via activation of the AKT pathway. Int Immunopharmacol. 2025;145:113750. https:\/\/doi.org\/10.1016\/j.intimp.2024.113750.","journal-title":"Int Immunopharmacol"},{"issue":"13","key":"1918_CR18","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1245\/s10434-019-07741-w","volume":"26","author":"HD M\u00fcller","year":"2019","unstructured":"M\u00fcller HD, Posch F, Suppan C, Bargfrieder U, Gumpoldsberger M, Hammer R, Hauser H, Dandachi N, Prein K, Stoeger H, Lax S, Balic M. Validation of residual cancer burden as prognostic factor for breast cancer patients after neoadjuvant therapy. Ann Surg Oncol. 2019;26(13):4274\u201383. https:\/\/doi.org\/10.1245\/s10434-019-07741-w.","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"1918_CR19","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","volume":"35","author":"WF Symmans","year":"2017","unstructured":"Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol. 2017;35(10):1049\u201360.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1918_CR20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.lungcan.2013.07.016","volume":"82","author":"J Mazi\u00e8res","year":"2013","unstructured":"Mazi\u00e8res J, Brugger W, Cappuzzo F, Middel P, Frosch A, Bara I, Klingelschmitt G, Klughammer B. Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study. Lung Cancer. 2013;82(2):231\u20137.","journal-title":"Lung Cancer"},{"key":"1918_CR21","doi-asserted-by":"publisher","unstructured":"Binnewies M, Pollack JL, Rudolph J, Dash S, Abushawish M, Lee T, Jahchan NS, Canaday P, Lu E, Norng M, Mankikar S, Liu VM, Du X, Chen A, Mehta R, Palmer R, Juric V, Liang L, Baker KP, Reyno L, Krummel MF, Streuli M, Sriram V. Targeting TREM-2 on tumor-associated macrophages enhances immunotherapy. Cell Rep. 2021;37(3):109844. https:\/\/doi.org\/10.1016\/j.celrep.2021.109844.","DOI":"10.1016\/j.celrep.2021.109844"},{"issue":"10","key":"1918_CR22","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1007\/s00262-022-03173-w","volume":"71","author":"H Zhang","year":"2022","unstructured":"Zhang H, Liu Z, Wen H, Guo Y, Xu F, Zhu Q, Yuan W, Luo R, Lu C, Liu R, Gu J, Ge D, Immunosuppressive. TREM-2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer. Cancer Immunol Immunother. 2022;71(10):2511\u201322. https:\/\/doi.org\/10.1007\/s00262-022-03173-w.","journal-title":"Cancer Immunol Immunother"},{"key":"1918_CR23","doi-asserted-by":"publisher","first-page":"646523","DOI":"10.3389\/fimmu.2021.646523","volume":"12","author":"X Cheng","year":"2021","unstructured":"Cheng X, Wang X, Nie K, Cheng L, Zhang Z, Hu Y, Peng W. Systematic pan-cancer analysis identifies TREM-2 as an immunological and prognostic biomarker. Front Immunol. 2021;12:646523. https:\/\/doi.org\/10.3389\/fimmu.2021.646523.","journal-title":"Front Immunol"},{"key":"1918_CR24","doi-asserted-by":"publisher","first-page":"1498993","DOI":"10.3389\/fimmu.2024.1498993","volume":"15","author":"AB Sigalov","year":"2024","unstructured":"Sigalov AB. TREM-1 and TREM-2 as therapeutic targets: clinical challenges and perspectives. Front Immunol. 2024;15:1498993. https:\/\/doi.org\/10.3389\/fimmu.2024.1498993.","journal-title":"Front Immunol"},{"key":"1918_CR25","doi-asserted-by":"publisher","first-page":"734959","DOI":"10.3389\/fonc.2021.734959","volume":"11","author":"AK Pullikuth","year":"2021","unstructured":"Pullikuth AK, Routh ED, Zimmerman KD, Chifman J, Chou JW, Soike MH, Jin G, Su J, Song Q, Black MA, Print C, Bedognetti D, Howard-McNatt M, O\u2019Neill SS, Thomas A, Langefeld CD, Sigalov AB, Lu Y, Miller LD. Bulk and single-cell profiling of breast tumors identifies TREM-1 as a dominant immune suppressive marker associated with poor outcomes. Front Oncol. 2021;11:734959. https:\/\/doi.org\/10.3389\/fonc.2021.734959.","journal-title":"Front Oncol"},{"issue":"711","key":"1918_CR26","doi-asserted-by":"publisher","first-page":"eadd9990","DOI":"10.1126\/scitranslmed.add9990","volume":"15","author":"V Juric","year":"2023","unstructured":"Juric V, Mayes E, Binnewies M, Lee T, Canaday P, Pollack JL, Rudolph J, Du X, Liu VM, Dash S, Palmer R, Jahchan NS, Ramoth \u00c5J, Lacayo S, Mankikar S, Norng M, Brassell C, Pal A, Chan C, Lu E, Sriram V, Streuli M, Krummel MF, Baker KP, Liang L. TREM-1 activation of myeloid cells promotes antitumor immunity. Sci Transl Med. 2023;15(711):eadd9990. https:\/\/doi.org\/10.1126\/scitranslmed.add9990.","journal-title":"Sci Transl Med"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01918-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01918-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01918-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:02:45Z","timestamp":1792976565000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01918-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1918"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01918-4","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"4 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Trakya University Faculty of Medicine, Non-Interventional Clinical Research Ethics Committee (Approval No: 16\/29; Date: 23.10.2023; Protocol No: 2023\/409). Participants provided written informed consent before inclusion in the study.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}